Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-25-142037
Filing Date
2025-06-17
Accepted
2025-06-17 16:01:20
Documents
12
Period of Report
2025-05-29
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K/A d35713d8ka.htm   iXBRL 8-K/A 25132
  Complete submission text file 0001193125-25-142037.txt   140475

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fate-20250529.xsd EX-101.SCH 2878
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fate-20250529_lab.xml EX-101.LAB 17943
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fate-20250529_pre.xml EX-101.PRE 11265
15 EXTRACTED XBRL INSTANCE DOCUMENT d35713d8ka_htm.xml XML 4573
Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131
Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803
FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

EIN.: 651311552 | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36076 | Film No.: 251053237
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)